EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities

Luis Chinea, Caroline Hauer, Khushboo Pal, Hannah L Chang, Isaac S Chan

Targeted Oncology · 2026-09 · 21 (5) · 681-699

DOI: 10.1007/s11523-026-01232-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Targeted Oncology, online erschienen am 06.08.2026. Verfasst von Luis Chinea und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Robert J. and Claire Pasarow Foundation, Disease Oriented Scholars Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have significantly changed the treatment approach for hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative (HER2−) breast cancer in both metastatic and high-risk early-stage settings. In combination with endocrine therapy, these agents consistently improve progression-free survival, and several phase III trials have demonstrated overall survival benefit in defined populations. Their clinical activity is supported by a well-established biologic rationale targeting dysregulated cell cycle progression, a key feature of HR+ breast cancer, which drives tumor proliferation. Despite these advances, resistance remains a clinical limitation in advanced disease. Multiple mechanisms have been identified, including loss of RB1 function; amplification of CDK6, activation of cyclin E CDK2 signaling; upregulation of bypass pathways such as PI3K, AKT, mTOR, and FGFR; and acquired alterations in estrogen receptor signaling, including ESR1 mutations. Circulating tumor DNA assays are increasingly used in clinical practice and clinical trials to detect emerging genomic alterations that may allow earlier modification of therapy based on molecular progression. The post-CDK4/6-inhibitor treatment landscape has expanded substantially and now includes treatment options such as switching CDK4/6 inhibitors, targeting the PI3K–AKT pathway in patients selected for mutation, use of oral selective estrogen receptor degraders, and incorporation of antibody–drug conjugates. Ongoing studies evaluating CDK2 inhibitors, CDK4-selective agents, immunotherapy combinations, and circulating tumor DNA (ctDNA)-guided strategies aim to further refine treatment sequencing and improve long-term outcomes in HR+/HER2− breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsHumansFemaleDrug Resistance, Neoplasm

Substanzen

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA.
  • City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA. isaac.chan@utsouthwestern.edu.
  • Department of Molecular Biology, University of Texas Southwestern, Dallas, TX, USA. isaac.chan@utsouthwestern.edu.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-8845, USA. isaac.chan@utsouthwestern.edu.
  • Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern, Dallas, TX, USA. isaac.chan@utsouthwestern.edu.

Förderung

  • NCI NIH HHS
  • Robert J. and Claire Pasarow Foundation
  • Disease Oriented Scholars Award
  • National Cancer Institute

Zitieren

APA

Chinea, L., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026). CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities. Targeted Oncology, 21(5), 681-699. https://doi.org/10.1007/s11523-026-01232-1

Vancouver

Chinea L, Hauer C, Pal K, Chang HL, Chan IS. CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities. Targeted Oncology. 2026;21(5):681-699. doi:10.1007/s11523-026-01232-1

BibTeX
@article{Chinea2026,
  author = {Chinea, Luis and Hauer, Caroline and Pal, Khushboo and Chang, Hannah L and Chan, Isaac S},
  title = {CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities},
  journal = {Targeted Oncology},
  year = {2026},
  volume = {21},
  number = {5},
  pages = {681--699},
  doi = {10.1007/s11523-026-01232-1}
}
Kostenlos starten →